Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells $49,010.00 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 14,500 shares of the company’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $3.38, for a total transaction of $49,010.00. Following the sale, the chief executive officer directly owned 518,622 shares of the company’s stock, valued at $1,752,942.36. The trade was a 2.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.40, for a total transaction of $217,413.00.
• On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total transaction of $322,718.41.
• On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.51, for a total transaction of $359,406.45.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Price Performance

Whitehawk Therapeutics stock opened at $3.39 on Monday. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48. The firm has a market capitalization of $160.00 million, a price-to-earnings ratio of 7.21 and a beta of 0.57. The company has a fifty day simple moving average of $3.35 and a 200-day simple moving average of $2.72.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, March 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.21.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on WHWK. JonesTrading began coverage on shares of Whitehawk Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Friday, March 27th. Wall Street Zen lowered shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer started coverage on shares of Whitehawk Therapeutics in a report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $6.50.

Institutional Investors Weigh In On Whitehawk Therapeutics

Hedge funds have recently modified their holdings of the company. Quadrature Capital Ltd purchased a new stake in shares of Whitehawk Therapeutics in the fourth quarter valued at about $28,000. ABG Innovation Capital Partners III GP Ltd purchased a new stake in Whitehawk Therapeutics in the 3rd quarter valued at about $51,000. Dimensional Fund Advisors LP purchased a new stake in Whitehawk Therapeutics in the 3rd quarter valued at about $84,000. Marshall Wace LLP purchased a new position in Whitehawk Therapeutics during the fourth quarter worth about $164,000. Finally, Jane Street Group LLC boosted its stake in Whitehawk Therapeutics by 177.3% during the fourth quarter. Jane Street Group LLC now owns 69,931 shares of the company’s stock worth $169,000 after buying an additional 44,716 shares during the period. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.